Disease-Modifying Pharmacotherapy Discussion With Patient With ALS
Measure purpose: Ensure disease-modifying pharmacotherapy (DMP) is routinely discussed with patients with ALS.
The numerator: patients with whom the clinician discussed DMP (i.e., riluzole, edaravone, sodium phenylbutyrate/taurursodial, or other FDA-approved medication) at least once annually
is divided by
The denominator: patients diagnosed with ALS phenotypes characterized by appropriate ICD codes
There are no exclusions for this measure.
Key Phrases
Examples of key phrases you could use to meet the measure include:
- Patient DMP options reviewed
- Patient DMP changed following discussion
- Patient provided DMP counseling
Measure Calculation Example
Dr. Glovier has 76 patients between January 1 and December 31 that were diagnosed with ALS phenotypes characterized by appropriate ICD codes. This is the denominator.
There are no exclusions for this measure.
Dr. Glovier discusses disease-modifying pharmacotherapy with 38 patients. This is the numerator.
Quality of patient care = 38/76. Dr. Glovier has a score of 50% for this measure.